Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Patent Citations (4)

Non-Patent Literature (91)

• AI-Abdely et al., “Efficacies of KY62 Against Leishmania amazonensis and Leishmania donovani in Experimental Murine Cutaneous Leishmaniasis and Visceral Leishmaniasis” Antimicrob. Agents Chemother. 42:2542-2548 (1998).Applicant
• Andres et al., “Biochemical Effects of Chlorpromazine on Mouse Neuroblastoma Cells” Vet. Hum. Toxicol. 41:273-278 (1999).Applicant
• Bailly et al., “Sequence-Specific DNA Minor Groove Binders. Design and Synthesis of Netropsin and Distamycin Analogues” Bioconjug. Chem. 9:513-538 (1998).Applicant
• Bailly et al., “Sequence-Selective Binding to DNA of bis(amidinophenoxy) Alkanes Related to Propamidine and Pentamidine” Biochem. J. 323:23-31 (1997).Applicant
• Barak et al., “The Effect of Chlorpromazine and Haloperidol on DNA Transcription” Int. Clin. Psychopharmacol. 11:193-197 (1996).Applicant
• Beckett et al., “Metabolism of Chlorpromazine and Promazine in vitro: Isolation and Characterization of N-Oxidation Products” Xenobiotica 18:61-74 (1988).Applicant
• Bell et al., “Structure-Activity Relationships of Pentamidine Analogs Against Giardia lamblia and Correlation of Antigiardial Activity with DNA-Binding Affinity” Antimicrob. Agents Chemother. 35:1099-1107 (1991).Applicant
• Benaim et al., “A Calmodulin-Stimulated Ca 2+ Pump in Plasma-Membrane Vesicles from Trypanosoma brucei; Selective Inhibition by Pentamidine” Biochem J, 296:759-63 (1993).Applicant
• Bleeker et al., “The Effects of Dexamethazone and Chlorpromazine on Tumor Necrosis Factor-Alpha, Interleukin-1 Beta, Interleukin-1 Receptor Antagonist and Interleukin-10 in Human Volunteers” Immunology 91:548-552 (1997).Applicant
• Borsa et al., “Selective Cytotoxicity of Calmidazolium and Trifluoperazine For Cycling Verses Noncycling C3H10T1/2 cells In Vitro” Cancer Res. 46:133-136 (1986).Applicant
• Chen et al., “Anti-Tumor Necrosis Factor Properties of Non-Peptide Drugs in Acute-Phase Responses” Eur. J. Pharmacol. 271:319-327 (1994).Applicant
• Clancy et al., “Chlorpromazine Modulates Cytokine Expression in the Liver and Lung After Burn Injury and Endotoxemia” J. Trauma, 48:215-222 (2000).Applicant
• Corsini et al., “Induction of Tumor Necrosis Factor-Alpha In Vivo by a Skin Irritant, Tributytin, Through Activation of Transcription Factors: Its Pharmacological Modulation by Anti-Inflammatory Drugs” J. Invest. Dermatol. 108: 892-896 (1997).Applicant
• Cubria et al., “Aromatic Diamidines are Reversible Inhibitors of Porcine Kidney Diamine Oxidase” Biochem. Pharmacol. 45:1355-1357 (1993).Applicant
• Dautzenberg et al., “Pentamidine Aerosol in the Prevention Treatment of Pneumocystosis in AIDS Patients. Comparison of Two Salts and Two Nebulizers” Presse. Med. 20: 1117-1120 (1991).Applicant
• Del Poeta et al., “Structure-In Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents” Antimicrob. Agents Chemother. 42:2495-2502 (1998).Applicant
• Fimognari et al., “Flow Cytometric Analysis of Genetic Damage, Effect on Cell Cycle Progression, and Apoptosis by Thiophanate-Methyl in Human Lymphocytes” Environ. Mol. Mutagen. 33:173-176 (1999).Applicant
• Ferroni et al., “N1-Substituted Benzamidines: Synthesis, Antiproteinase Activity and Inhibition of Tumor Cell Growth” Farmaco 46:1311-1321 (1991).Applicant
• Herberich et al., “Synthesis of a Netropsin Conjugate of a Water-Soluble epi-Quinocarcin Analogue: the Importance of Stereochemistry at Nitrogen” Bioorganic & Medicinal Chemistry 8:523-532 (2000).Applicant
• Jansen et al, “Chlorpromazine Down-Regulates Tumor Necrosis Factor-Alpha and Attenuates Experimental Multiple Organ Dysfunction Syndrome in Mice” Crit. Care Med. 26:1244-1250 (1998).Applicant
• Jiang et al., “Transformation of Lupus-Inducing Drugs to Cytotoxic Products by Activated Neutrophils” Science 266:810-813 (1994).Applicant
• Jones, “Successful Cancer Therapy with Promethazine: The Rationale” Med. Hypotheses, 46:25-29 (1996).Applicant
• Kim et al., “Effects of Calmodulin Antagonists and Anesthetics on the Skin Lesions Induced by 2-Chloroethylethyl Sulfide” Eur. J. Pharmacol. 313:107-114 (1996).Applicant
• Kitamura et al., “Inhibition of Constitutive Nitric Oxide Synthase In the Brain by Pentamidine, a Calmodulin Antagonist” Eur. J. Pharmacol. 289:299-304 (1995).Applicant
• Krishan et al., “Synergistic Effects of Prochlorperazine and Dipyridamole on the Cellular Retention and Cytotoxicity of Doxorubicin” Clinical Cancer Research 6:1508-1517 (2000).Applicant
• Kumar et al., “Inhibition of Protein Synthesis by Antagonists of Calmodulin in Ehrlich Ascites Tumor Cells” Eur. J. Biochem. 195:313-319 (1991).Applicant
• Mesa-Valle et al., “In Vitro Action of Platinum (II) and Platinum (IV) Complexes on Trypanosoma cruzi and Leishmania donovani” Arzneimittelforschung 39:838-842 (1989).Applicant
• Mesa-Valle et al., “In Vitro and In Vivo Activity of Two Pt(IV) Salts Against Leishmania donovani” Pharmacology 57:160-72 (1998).Applicant
• Mesa-Valle CM et al., “Action of New Organometallic Complexes Against Leishmania donovani” J. Antimicrob. Chemother. 40:47-57 (1997).Applicant
• Mongiardo et al., “Pentamidine Salts” Lancet 2:108 (1989).Applicant
• Navas et al., “Structural Determinants of Putrescine Uptake Inhibition Produced by Cationic Diamidines in the Model of Trypanosomatid Crithidia Fasciculata” Biol. Chem. 377:833-836 (1996).Applicant
• Nunn et al., “Sequence-Dependent Drug Binding to the Minor Groove of DNA: Crystal Structure of the DNA Dodecamer d(CGCAAATTTGCG)2 Complexed with Propamidine” J. Med. Chem. 38:2317-2325 (1995).Applicant
• Ohtsuka et al., “Inhibitory Effect on LPS-Induced Tumor Necrosis Factor in Calves Treated with Chlorpromazine or Pentoxifylline” J. Vet. Med. Sci. 59:1075-1077 (1997).Applicant
• Palmer et al., “Correlation of Activity of Chlorpromazine and Respective Hydroxy, Dimethoxy and Sulphoxide Analogues on Dopamine, Muscarinic, Histamine and Calmodulin Sites of Action” Xenobiotica 18:277-289 (1988).Applicant
• Perez et al., “DNA Binding Properties and Antileukemic (L1210) Activity of Pt-Pentamidine Complex” Chem. Biol. Interact, 77:341-55 (1991).Applicant
• Perez et al., “Binding of Pt-Pentamidine to Nucleosomal DNA. Studies of the Antiproliferative Activity of the Drug Against Human Cancer Cells” Chemico-Biological Interactions 89:61-72 (1993).Applicant
• Prokopenko et al., “Effects of Haloperidol and Chlorpromazine on Smooth Muscle Contractility, Platelet Aggregation an Neuronal Calcium Current” Gen. Physiol. Biophys. 14:349-357 (1995).Applicant
• Rosenthal et al., “Pentamidine: An inhibitor of Interleukin-1 that Acts Via a Post-Translational Event” Toxicol. Appl. Pharmacol. 107:555-561 (1991).Applicant
• Smid et al., “Radiotherapy, Combined with Simultaneous Chemotherapy with Mitomycin C and Bleomycin for Inoperable Head and Neck Cancer-Preliminary Report” Int. J. Radiat. Oncol. Biol. Phys. 32:769-75 (1995).Applicant
• Syed et al., “Reversal of Vinblastine Transport By Chlorpromazine in Membrane Vesicles from Multidrug-Resistant Human CCRF-CEM Leukaemia Cells” Br. J. Cancer 78:321-7 (1998).Applicant
• Tidwell et al., “Analogues of 1,5-Bis(4-amidinophenoxy)pentane (Pentamidine) in the Treatment of Experimental Pneumocystis carinii Pneumonia” J. Med. Chem. 33:1252-1257 (1990).Applicant
• Ueda et al., “Chloropromazine Reduces Toxicity and Ca2+ Uptake Induced by Amyloid Beta Protein (25-35) In Vitro” Brain Res, 748:184-8 (1997).Applicant
• Van Wauwe et al., “The Inhibitory Effect of Pentamidine on the Production of Chemotactic Cytokines by In Vitro Stimulated Human Blood Cells” Inflamm. Res. 45:357-63 (1996).Applicant
• Zakrzewska et al., “The Solvation Contribution to the Binding Energy of DNA with Non-Intercalating Antibiotics” Nucleic Acids Res. 12:6559-74 (1984).Applicant
• Snapper, I., “Stilbamidine and Pentamidine in Multiple Myeloma,” J.A.M.A., 133:157-161., 1947.Applicant
• Snapper, I., “On the Influence of Stilbamidine Upon Multiple Myeloma,” Journal of the Mount Sinai Hospital, 8:119-127, 1946.Applicant
• Syed et al., “Reversal of Vinblastine Transport by Chlorpromazine in Membrane Vesicles from Multidrug-Resistant Human CCRF-CEM Leukaemia Cells,” British Journal Of Cancer, 78:321-327, 1998.Applicant
• Tsuruo et al., “Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and In Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil,” Cancer Research, 41:1967-1972, 1981.Applicant
• Tsuruo et al., “Increased Accumulation of Vincristine and Adriamycin in Drug Resistant P388 Tumor Cells Following Incubation with Calcium Antagonist and Calmodulin Inhibitors,” Cancer Research, 42:4730-4733, 1982.Applicant
• Tsuruo et al., “Potentiation of Antitumor Agents by Calcium Channel Blockers with Special Reference to Cross Resistance Patterns,” Cancer Chemotherapy and Pharmacology, 15:16-19, 1985.Applicant
• Turner et al., “The Mutagenic Properties of DNA Minor-Groove Binding Ligands,” Mutation Research, 355:141-169, 1996.Applicant
• Waalkes et al., “Pentamidine” Clinical Pharmacologic Correlations in Man and Mice, Clinical Pharmacology & Therapeutics, 11:505-512, 1970.Applicant
• Wils et al., “Polarized Transport of Docetaxel and Vinblastine Mediated by P-Glycoprotein in Human Intestinal Epithelial Cell Monolayers,” Biochemical Pharmacology, 48:1528-1530, 1994.Applicant
• Zakotnik et al., “Concomitant Radiotherapy with Mitomycin C and Bleomycin Compared with Radiotherapy Alone in Inoperable Head and Neck Cancer: Final Report,” Int. J. Radiation Oncology Biol. Phys., 41:1121-1127, 1998.Applicant
• National Cancer Institute Developmental Therapeutics Program In-vitro Testing Results, NSC 620107 Experiment ID 9407SR53-57, 1994.Applicant
• Fibach et al., “Phorbol Ester-Induced Adhesion of Murine Erythroleukemia Cells: Possible Involvement of Cellular Proteases,” Carcinogenesis, 4:1395-1399, 1983.Applicant
• Ford et al., “Structural Features Determining Activity of Phenothiazines and Related Drugs for Inhibition of Cell Growth and Reversal of Multidrug Resistance,” Molecular Pharmacology, 35:105-115, 1989.Applicant
• Fraser et al., “Endo-Exonuclease of Human Leukaemic Cells: Evidence for a Role in Apoptosis,” J. Cell Sci., 109:2343-2360, 1996.Applicant
• Gambari et al., “DNA-Binding Activity and Biological effects of Aromatic Polyamidines,” Biochem Pharmacol, 47:599-610, 1994.Applicant
• Ganapathi et al., “Factors Governing the Modulation of Vinca-Alkaloid Resistance in Doxorubicin-Resistant Cells by the Calmodulin Inhibitor Trifluoperazine.” Biochemical Pharmacology, 35:673-678, 1986.Applicant
• Hait et al., “Antitumor and Toxic Effects of Combination Chemotherapy with Bleomycin and a Phenothiazine Anticalmodulin Agent,” J. Natl. Cancer Inst., 80:246-250, 1988.Applicant
• Huilgol et al., “Assessment of Chlorpromazine as Radiation Sensitizer and Protector,” Indian Journal of Cancer, 31:195-200, 1996.Applicant
• Huilgol et al., “A clinical Study to Assess Chloropromazine as Hypoxic Cell Sensitizer in Head and Neck Cancer Treated with Conventional Radiation,” Indian Journal of Cancer, 35:97-100, 1998.Applicant
• Ishikawa et al., “Exacerbation of Doxorubicin Lethality by Chlorpromazine in Mice,” Jpn. J. Pharmacol. 55:300P, p-291, 1991.Applicant
• Ishikawa et al., “Protection Against Cisplatin and Doxorubicin Toxicity in BALB/C Mice by Chloropromazine Hypothemia,” Research Communications in Psychology, Psychiatry, and Behavior, 16:93-96, 1991.Applicant
• Klemes et al., “Inhibition of Phorbol-Ester-Induced Adhesion of Differentiating Human Myeloid Leukemic Cells by pentamidine-Isethionate,” Differentiation, 27:141-145, 1984.Applicant
• Kopac, M.J., “Section of Biology,” The New York Academy of Sciences, 5-10, 1945.Applicant
• Kopac, M.J., “Some Cellular and Surface Chemical Aspects of Tumor Chemotherapy,” in Approaches to Tumor Chemotherapy ed. F.R. Moulton, AAAS, Washington, D.C. 1947.Applicant
• Akiyama et al., “Circumvention of Multiple-Drug Resistance in Human Cancer Cells by Thioridazine, Trifluoperazine, and Chlorpromazine.” J. Natl. Cancer Inst., 76:839-844, 1986.Applicant
• Anees et al., “Inhibition of a Tumor Protease with 3,4-Dichloroisocoumarin, Pentamidine-Isethionate and Guanidino Derivatives,” J. Enzyme Inhibition, 8:213-221, 1994.Applicant
• Barancik et al., “Reversal effects of Several Ca2+ Entry Blockers, Neuroleptics and Local Anesthetics on P-Glycoprotein Mediated Vincristine Resistance of L1210/VCR Mouse Leukaemic Cell Line.” Drugs Exptl. Clin. Res., 20:13-18 1994.Applicant
• Barrett et al., “Anti-Sleeping Sickness Drugs and Cancer Chemotherapy,” Parasitology Today, 16:7-9, 2000.Applicant
• Bebawy et al., “Selective Modulation of P-Glycoprotein-Mediated Drug Resistance.” Brit. J. Cancer, 85:1998-2003, 2001.Applicant
• Bornstein et al., “An Evaluation of the Mechanism of Action of Pentamidine Isethionate,” Journal of Surgical Oncology, 2:393-398, 1970.Applicant
• Cresson et al., “In Vitro Inhibition of Human Sarcoma Cells' Invasive Ability by Bis(5-Amidino-2-Benzimidazolyl) Methane-a novel esteroprotease inhibitor,” Am. J. Pathol. 123:46-56, 1986.Applicant
• Darkin et al., “Chlorpromazine: A Potential Anticancer Agent?” Biochem. Biophys. Res. Commun., 125:184-191, 1984.Applicant
• Driscoll et al., “Pyschotropic Drugs as Potential Antitumor Agents: A Selective Screening Study.” Cancer Treatment Rep., 62:45-74, 1978.Applicant
• Ferroni et al., “N1-Substituted Benzamidines: Synthesis, Antiproteinase Activity and Inhibition of Tumor Cell Growth,” II Farmaco, 46:1311-1321, 1991.Applicant
• Libby et al., “Inhibition of Enzymes of Polyamine Back-Conversion by Pentamidine and Berenil,” Biochemical Parmacology, 44:830-832, 1992.Applicant
• Luck et al., “Interaction of Nonintercalative Antitumour Drugs SN-6999 and SN-18071 with DNA: Influence of Ligand Structure on the Binding Specificity,” Journal of Biomolecular Structure & Dynamics 4:1079-1094, 1987.Applicant
• Miller et al., “Clinical Modulation of Doxorubicin Resistance by the Calmodulin Inhibitor, Trifluoperazine: A Phase I/II Trial,” Journal of Clinical Oncology, 6:880-888, 1988.Applicant
• Naito et al., “Competitive Inhibition by Verapamil of ATP-Dependent High Affinity Vincristine Binding to the Plasma Membrane of Multidrug Resistant K562 Cells Without Calcium Ion Involvement,” Cancer Research, 49:1452-1455, 1989.Applicant
• Nastruzzi et al., “Inhibition of ‘In Vitro’ Tumor Cell Growth by Aromatic Polyamidines Exhibiting Antiproteinase Activity,” Clin. Expl. Metastasis, 7:25-39, 1989.Applicant
• Nastruzzi et al., “Differential Effects of Benzamidine Derivatives on the Expression of C-MYC and HLA-DRα Genes in a Human B-Lymphoid Tumor Cell Line,” Cancer Letters, 38:297-305, 1988.Applicant
• Nishimura et al., “A Serine Protease-Inhibitory Benzamidine Derivative Inhibits the Growth of Human Colon Carcinoma Cells,” Jpn. J. Cancer Res., 83:723-728, 1992.Applicant
• Nordenberg et al., “Effects of Psychotropic Drugs on Cell Proliferation and Differentiation,” Biochemical Pharmacology, 58:1229-1236, 1999.Applicant
• Osei et al., “Diabetogenic Effect of Pentamidine,” Am. J. Med., 77:41-46, 1984.Applicant
• Reddy et al., “Synthetic DNA Minor Groove-Binding Drugs,” Pharmacology & Therapeutics, 84:1-111, 1999.Applicant
• Sands et al., “Pentamidine: A Review,” Reviews of Infectious Diseases, 7:625-634, 1985.Applicant
• Sansom et al., “Structural Studies on Bio-Active Compounds. Part XIV. Molecular Modeling of the Interactions Between Pentamidine and DNA,” Anti-Cancer Drug Design, 5:243-248, 1990.Applicant
• Schoenbach et al., “The Pharmacology, Mode of Action and Therapeutic Potentialities of Stilbamidine, Pentamidine, Propamidine and Other Aromatic Diamidines-A Review,” Medicine, 27:327-377, 1948.Applicant